The results suggest that semaglutide is psychiatrically safe for patients with obesity who have no major history of mental health disorders, Kushner said.
Since 2012, the FDA has required all medications registered for treatment of obesity to assess participants for suicidal ideation or suicidal behavior," Kushner said. "That's because of previous medications that have caused those side effects.
Both groups had no clinically meaningful change in average depression score, however, patients on semaglutide were 37 percent less likely to change to a more severe level of depression than those who received placebo.
We had an opportunity to look at participants prospectively and assess them at fixed times regarding their overall mood, depression and thoughts of suicidal ideation or behavior," Kushner said.
Collection
[
|
...
]